Clinical trials: Clinically Significant Prostate Cancer
Prostate Cancer, Magnetic Resonance Imaging
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa).
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy
- Trial name
- NCT03044197
- Testing
- MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Prostate Cancer, Clinically Significant Prostate Cancer
Transperineal Versus Transrectal Cognitive Fusion Prostate Biopsy
This prospective randomized controlled trial aims to compare transperineal and transrectal cognitive fusion prostate biopsy techniques in patients with suspicious prostate lesions detected by multiparametric magnetic resonance…
- Conditions
- Prostate Cancer, Clinically Significant Prostate Cancer, Cognitive Fusion
- Trial name
- PROCOG (NCT07710807)
- Testing
- Transrectal Cognitive Fusion Prostate Biopsy, Transperineal Cognitive Fusion Prostate Biopsy
- Where
- Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Ankara Etlik City Hospital
Prostate Carcinoma
Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
This clinical trial studies whether transperineal micro-ultrasound can be used to detect prostate cancer during biopsy. Transrectal ultrasound is often used during prostate biopsy.
- Trial name
- NCT07075705
- Testing
- Biopsy of Prostate, Magnetic Resonance Imaging, Micro-ultrasound Imaging
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Roswell Park Cancer Institute
Prostate CA
Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management
Prostate cancer is the most common male cancer in 112 countries and makes up 7% of global cancer cases, and is the second leading cause of cancer-related deaths in men.
- Trial name
- PARADIGM (NCT07647445)
- Testing
- AI (Lucida Pi) interpretation, Radiologist interpretation
- Volunteers
- 500 people
- Sponsor
- University College, London
Low Risk Prostate Cancer, Clinically Significant Prostate Cancer
Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance
This is a multicenter, prospective diagnostic accuracy study evaluating the Istanbul PSMA PET/CT Criteria (IPPC) for selecting patients with biopsy-confirmed low-risk prostate cancer (ISUP Grade 1) for active surveillance (AS).
- Trial name
- I-SELECT (NCT07168616)
- Testing
- Ga-68 PSMA11 PET/CT
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 201 people
- Sponsor
- Istanbul University - Cerrahpasa
Prostate Cancer
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
This is a phase II, single-center, open-label, trial to evaluate the diagnostic accuracy of PSMA-targeted 18F-DCFPyL PET/CT for detecting clinically significant prostate cancer in a screening population.
- Trial name
- NCT03471650
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Diagnosis
PSMA PET Scan and mpMRI for Prostate Cancer Detection
Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.
- Trial name
- NCT05820724
- Testing
- PSMA PET scan, No PSMA PET, 18F- DCFPyl Injection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostate Cancer
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy.
- Trial name
- IBIS-PC (NCT07795723)
- Testing
- MRI/US Cognitive Fusion Targeted Biopsy Plus Ipsilateral Systematic Biopsy, MRI/US Cognitive Fusion Targeted Biopsy Plus Bilateral Systematic Biopsy
- Where
- China
- Volunteers
- 454 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
This project aims to evaluate the role of fully hybrid PET/MRI with 18F-PSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa).
- Trial name
- NCT05815316
- Testing
- 18F-PSMA-1007
- Sponsor
- IRCCS San Raffaele
Prostate Cancer, Prostate Cancer Screening
Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
This ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy…
- Conditions
- Prostate Cancer, Prostate Cancer Screening, Performance Assessment of Novel Test
- Trial name
- APCaRI-05 (NCT03957252)
- Where
- 3 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Nanostics
Prostate Cancer
Cancer Diagnosis by Multiparametric UltraSound of the Prostate
In men who require a prostate biopsy does a multi-parametric ultrasound based diagnostic strategy compared to a multi-parametric MRI based diagnostic strategy lead to similar detection of clinically significant prostate cancer?
- Trial name
- CADMUS (NCT02712684)
- Testing
- multiparametric MRI. Multi-parametric ultrasound
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University College, London
Prostatic Neoplasm of Uncertain Behavior
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Study Goal: The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared…
- Trial name
- Biopsy29 (NCT06579911)
- Testing
- High-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Prostatic Neoplasms, Prostate Cancer
Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer
This trial uses a ultra high-resolution ultrasound system and specialized transducer, intended for use in prostate imaging. The system's image resolution is significantly better than the standard of care, due to its higher…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02079025
- Testing
- High-resolution ultrasound guided prostate biopsy, Standard ultrasound guided prostate biopsy
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,676 people
- Sponsor
- Exact Imaging
Prostate Carcinoma
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater than or equal to 2 ng/mL.
- Trial name
- NCT04910425
- Testing
- Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Sponsor
- Northwestern University
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
Health Status Unknown, Elevated PSA
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific…
- Trial name
- NCT03234556
- Testing
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- 4 sites in United States
- Volunteers
- 288 people
- Sponsor
- University of Southern California
Prostate Cancer
Comparison of a Novel Transperineal Targeted Fusion Biopsy System to Conventional Transrectal Targeted Fusion Biopsy
This study is designed as a randomized control trial which intends to determine if transperineal (TP) targeted biopsy is not inferior to transrectal (TR) targeted biopsy for diagnosis of clinically significant prostate cancer…
- Trial name
- NCT03936127
- Testing
- Ultrasound (US) Targeted Fusion Biopsy
- Where
- Canada
- Volunteers
- 360 people
- Sponsor
- Dr. Nicola Schieda
Prostate Cancer (Diagnosis), Prostate Cancer
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures.
- Trial name
- INSIGHT-PCa (NCT07398690)
- Testing
- Diagnostic Procedure
- Where
- South Korea
- Volunteers
- 1,432 people
- Sponsor
- In Gab Jeong, MD
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University